Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Latent TB occurs when a person has the TB bacteria within their body, but the bacteria are present in very small numbers. They are kept under control by the body’s immune system and do not cause any symptoms.
People with latent TB do not feel sick and are not infectious. They cannot pass the bacteria on to other people. In addition they will usually have a normal chest x-ray and a negative sputum test. It is often only known that someone has latent TB because they have had a test, such as the TB skin test.
The treatment of latent TB is considered by many people to be an important part of TB prevention.
It is not recommended that everyone with latent TB infection (LTBI) should have TB treatment. Rather it is recommended that certain “target” groups should receive treatment. The main “target” groups considered by the World Health Organisation (WHO) to be most at risk from progressing from latent to active TB include people in low TB burden countries:
who have had recent contact with an infectious patient;
with silicosis;
infected with both TB and HIV;
who have been or who are in prison;
who are immigrants to a low burden country from a high burden country;
who are homeless;
who are an illicit drug user;
who have certain clinical conditions, or conditions which compromise their immune system, such as people with diabetes, and people with chronic renal failure.
In high TB burden countries the populations that are most strongly recommended for the treatment of latent TB infection are people living with HIV, and children under five who are household contacts of pulmonary TB cases.
The Tuberculosis Drugs market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Tuberculosis Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Tuberculosis Drugs market.
Major Players in the Tuberculosis Drugs market are:
Cadila Pharmaceuticals
Alkem Laboratories Ltd
AstraZeneca Plc
Lupin Laboratories Ltd
Cipla Ltd
Pfizer Inc
Novartis AG
On the basis of types, the Tuberculosis Drugs market is primarily split into:
First-line Anti-TB Drugs
Second-line Anti-TB Drugs
On the basis of applications, the market covers:
Latent TB
Active TB
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
2021
People with latent TB do not feel sick and are not infectious. They cannot pass the bacteria on to other people. In addition they will usually have a normal chest x-ray and a negative sputum test. It is often only known that someone has latent TB because they have had a test, such as the TB skin test.
The treatment of latent TB is considered by many people to be an important part of TB prevention.
It is not recommended that everyone with latent TB infection (LTBI) should have TB treatment. Rather it is recommended that certain “target” groups should receive treatment. The main “target” groups considered by the World Health Organisation (WHO) to be most at risk from progressing from latent to active TB include people in low TB burden countries:
who have had recent contact with an infectious patient;
with silicosis;
infected with both TB and HIV;
who have been or who are in prison;
who are immigrants to a low burden country from a high burden country;
who are homeless;
who are an illicit drug user;
who have certain clinical conditions, or conditions which compromise their immune system, such as people with diabetes, and people with chronic renal failure.
In high TB burden countries the populations that are most strongly recommended for the treatment of latent TB infection are people living with HIV, and children under five who are household contacts of pulmonary TB cases.
The Tuberculosis Drugs market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Tuberculosis Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Tuberculosis Drugs market.
Major Players in the Tuberculosis Drugs market are:
Cadila Pharmaceuticals
Alkem Laboratories Ltd
AstraZeneca Plc
Lupin Laboratories Ltd
Cipla Ltd
Pfizer Inc
Novartis AG
On the basis of types, the Tuberculosis Drugs market is primarily split into:
First-line Anti-TB Drugs
Second-line Anti-TB Drugs
On the basis of applications, the market covers:
Latent TB
Active TB
Major Region
s or countries covered in this report:United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
Years considered for this report:
Historical Years:
2017-2021Base Year:
2021Estimated Year:
2022Forecast Period:
2022-2029Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
